Economic evaluation of human papilloma virus vaccination in the European Union: a critical review

摘要: The human papilloma virus (HPV) vaccine is a new and expensive potentially effective in the prevention of cancer. We reviewed economic evaluations (EEs) on EU to assess their potential contribution public decision-making fairly homogeneous setting where HPV vaccination has been widely adopted. A literature search PubMed selected EEs vaccines for period 2007–2010 using terms “HPV vaccines” “Costs cost analysis.” Fifteen articles were eventually selected. All studies based modelling techniques, either “cohort” or “dynamic transmission”: three utility, cost-effectiveness, remainder included both. ten explicitly assessing one two all sponsored by manufacturer, while five unrelated type funded agencies. Apart from studies, utility estimates always obtained US sources. Direct costs vaccination, diagnosis treatment related pathologies. Incremental cost-effectiveness ratio (ICER) results less favourable when life years gained valued rather than quality-adjusted years, genital warts excluded, booster doses extension men base-case analysis. but recommend favour strategy, which dominant English study. ICER very sensitive discount rates, followed duration protection price. At such an early stage, vaccines’ efficacy have demonstrated well-designed it not possible (and even reasonable) wait several measure effectiveness; decision-makers might benefit more designed indicate sustainable prices realistic crucial variables like coverage referring large number assumptions order show acceptable cost-effectiveness.